Home / Comparisons / BPC-157 vs TB-500: What the Evidence Shows
BPC-157 vs TB-500: What the Evidence Shows
BPC-157 and TB-500 are sometimes marketed together. What studies exist for each, how HHS's Oct. 30 policy treats them, and why they aren't the same.
On this page
Side by side
| Question | BPC-157 | TB-500 |
|---|---|---|
| U.S. status | ||
| Strongest evidence | Limited human data | Animal studies |
| Status verified |
They are sometimes marketed together, but they are different substances with different evidence. Here is how the two compare on what has actually been tested, how HHS’s new policy treats them, and what no one has studied.
Key takeaways
- Neither BPC-157 nor TB-500 is FDA-approved for any use.
- We found no study comparing them or testing the two together. Claims that the combination works are not backed by a controlled trial we could find.
- BPC-157 has a few small human reports. For TB-500, FDA identified no clinical studies. Both have animal data, and neither has an established benefit in people.
- On Oct. 30, 2026, HHS published an interim policy covering both, saying it does not intend to take enforcement action against certain compounding, under conditions. It is not an approval, and it does not cover products that mix the two.
- TB-500 is not thymosin beta-4. FDA says they are not the same substance, so studies of one do not describe the other.
Are BPC-157 and TB-500 the same thing?
No. They are two different peptides that are sometimes marketed together.
- BPC-157 is reported to be a 15-amino-acid fragment of a protein originally isolated from human gastric juice.
- TB-500 is a short synthetic fragment of thymosin beta-4. FDA says “thymosin beta-4 and TB-500 are not the same substance.” Thymosin beta-4 is a natural protein of 43 amino acids; many websites use the two names as synonyms.
The confusion matters because there are human trials of full-length thymosin beta-4, and FDA identified none of TB-500. Those trials tested eye drops for dry eye (phase 3, 700 participants) and topical treatment of leg ulcers (phase 2, 72 participants), the latter with a primary goal of safety. They are not evidence about injected TB-500.
How do they compare?
| BPC-157 | TB-500 | |
|---|---|---|
| FDA approval | None; not a component of an approved product in any country, per FDA | None |
| HHS interim policy (Oct. 30, 2026) | Covers BPC-157 acetate: subcutaneous, intramuscular, oral and topical, under conditions | Covers TB-500 acetate: subcutaneous or intramuscular only, under conditions. The policy does not name full-length thymosin beta-4 |
| Advisory committee vote on listing | 8–6–1 in favor (law-firm account, secondary source). FDA’s drug center proposed not listing it | 8–6–1 in favor (same source). FDA’s drug center proposed not listing it |
| Controlled human studies | Two small placebo-controlled studies, both reported only in conference abstracts: a phase 1 tolerability study and a trial in ulcerative colitis. FDA describes a “lack of evidence” of effectiveness | None. FDA identified no clinical studies or human exposure data for TB-500 by any route |
| Other human data | A few small uncontrolled reports (knee, bladder, intravenous safety) | None identified |
| Animal data | Many models; effects in tendon, muscle, bone and ligament described as “promising but variable” in a scoping review of six peptides | Horses and rats: reaches the bloodstream and breaks into fragments. FDA says it remains unknown whether it has wound-healing properties in living animals |
| Safety knowledge | “Insufficient clinical safety information”; animal signals potentially related to clotting and the liver | Unknown; FDA identified no clinical or toxicity studies |
| Anti-doping (WADA) | Prohibited at all times (class S0) | Prohibited (class S2) |
Sources: FDA’s advisory committee presentations, FDA briefings on BPC-157 and TB-500, the HHS policy, the 2026 scoping review and the WADA 2026 list.
What are the human studies of BPC-157?
Small, and none establishes a benefit. FDA found two small placebo-controlled studies, both only in conference abstracts: a phase 1 study that randomized 32 healthy volunteers (24 on BPC-157) and tested tolerability, not whether it treats anything, and an ulcerative colitis trial in 53 people, where FDA said details were missing and described a “lack of evidence” of effectiveness. The uncontrolled reports are a retrospective knee series (17 people, some also given thymosin beta-4), a bladder pilot (12) and an intravenous safety pilot (2). A randomized pilot after rotator cuff surgery (NCT07803250, 30 people) was registered but not yet recruiting when we checked.
Our BPC-157 guide has the full detail.
Is there any evidence for the combination?
No. We found no published study of BPC-157 and TB-500 given together, and for TB-500 FDA identified no clinical studies. The human mentions of the pairing that we found are safety reports, not evidence of benefit. Among three adverse event reports FDA cites for BPC-157, one describes skin and gum darkening that returned on re-exposure in a person using BPC-157 with TB-500; causality is uncertain, and the reporting system is voluntary. FDA’s TB-500 briefing also lists two reports about a blended product, with no safety assessment.
A 2026 scoping review of six peptides, including both, concluded that their claimed benefits remain unsubstantiated by current human trials. For what that means for injuries, see our guide to peptides for injury recovery.
How does the HHS policy treat them?
On Oct. 30, 2026, HHS published an interim enforcement discretion policy covering six peptides, including these two. HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound them under section 503A, as long as all the policy’s conditions are met. Those include exact identification of the substance, batch testing, a registered and CGMP-compliant manufacturer, adverse-event reporting, a “compounded drug product” label, a single active ingredient, and a patient-specific prescription.
- It is not FDA approval. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.
- A blend of the two is not covered. A product with both involves two active ingredients (Frier Levitt, secondary source; the single-ingredient condition is in HHS’s text).
- It is interim and open to comment. The docket lists a closing date of Nov. 13, 2026 (Eastern time).
- Before the policy was issued, boards in Alabama and Mississippi told licensees they may not compound, administer or dispense non-FDA-approved or research-grade peptides. We found no update from them as of Oct. 31, and it isn’t clear how those notices apply to compounding under the HHS policy.
Where do HHS and FDA’s reviewers disagree?
We present both and do not choose.
| HHS (policy) | FDA (documents above) | |
|---|---|---|
| BPC-157 routes | Covers subcutaneous, intramuscular, oral and topical; cites “multiple human studies” without naming them | Found no human studies by oral, subcutaneous, nasal or transdermal routes, and its list of human studies does not include the intramuscular route |
| TB-500 evidence | Points to the human safety record of the parent protein | Says TB-500 and thymosin beta-4 are different substances and identified no clinical studies or human exposure data for TB-500 |
| Historical use | Describes it as “documented and quantified” | Says it could not identify pharmacies compounding TB-500, and that no outsourcing facility has reported compounding it. For BPC-157, says there is insufficient information on how long it has been compounded. HHS’s usage data are not published in the text we read |
FDA’s review (July) came before the HHS policy (October), so FDA has not answered HHS’s points directly. As we read it, whether the safety record of a whole protein applies to one of its fragments is an open question.
Which claims are not supported?
- “The stack heals tendons and joints.” We found no controlled study of the combination.
- “TB-500 is synthetic thymosin beta-4.” FDA says they are different substances.
- “They are legal now” or “FDA approved.” Neither. It is interim enforcement discretion, under conditions.
- “A BPC-157 plus TB-500 blend is covered.” The policy requires a single active ingredient.
- “No side effects reported means safe.” Few reports do not mean safety, and reporting is voluntary.
What should you ask your doctor?
- What is my diagnosis, and what does the evidence say about the standard treatments for it?
- If a peptide is suggested, what human evidence supports it for my condition, and is it BPC-157, TB-500 or a blend?
- Who prepares it, and does it meet the policy’s conditions (identity, testing, labeling, single ingredient)?
- Do I compete in a tested sport? Both are prohibited by WADA.
We do not give doses, cycles or preparation instructions, and we do not recommend sellers.
Frequently asked questions
Which is better, BPC-157 or TB-500?
Neither has an established benefit in people. BPC-157 has a few small human reports; for TB-500, FDA identified no clinical studies.
Can you take BPC-157 and TB-500 together?
We found no controlled study of the combination, and the HHS policy does not cover products with two active ingredients.
Are BPC-157 and TB-500 legal?
Neither is FDA-approved. HHS said it does not intend to take enforcement action against certain compounding of both, under conditions, on an interim basis. That is not an approval or a legalization.
Is TB-500 the same as thymosin beta-4?
No. FDA says they are not the same substance.
Sources we checked
- FDA presentations to the Pharmacy Compounding Advisory Committee (July 23, 2026)FDA. Accessed .
- FDA briefing document on BPC-157FDA. Accessed .
- FDA briefing document on TB-500FDA. Accessed .
- FDA CDER proposal on seven peptides (July 2026)FDA. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS policy, Appendix BOther. Accessed .
- Regulations.gov docket HHS-OASH-2026-0496Other. Accessed .
- McDermott+: PCAC votes on peptides (secondary source)Other. Accessed .
- Frier Levitt analysis of the HHS policy (secondary source)Other. Accessed .
- Alabama Board of Medical Examiners: notice on prescribing non-FDA-approved research-grade peptidesOther. Accessed .
- Mississippi nursing, pharmacy and medical licensure boards: joint statement on peptides (Aug. 19, 2026)Other. Accessed .
- Lee & Padgett 2021, knee injections (PubMed)PubMed. Accessed .
- Lee 2024, interstitial cystitis (PubMed)PubMed. Accessed .
- Lee & Burgess 2025, intravenous safety (PubMed)PubMed. Accessed .
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine, Am J Sports Med 2026 (PubMed)PubMed. Accessed .
- ClinicalTrials.gov NCT03937882 (thymosin beta-4, dry eye, phase 3)ClinicalTrials.gov. Accessed .
- ClinicalTrials.gov NCT00832091 (thymosin beta-4, venous ulcers, phase 2)ClinicalTrials.gov. Accessed .
- ClinicalTrials.gov NCT07803250 (BPC-157, rotator cuff pilot, not yet recruiting)ClinicalTrials.gov. Accessed .
- WADA 2026 Prohibited ListOther. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.